Corline Biomedical AB (CLBIO) Stock Statistics & Valuation Metrics

Corline Biomedical AB has a market cap or net worth of kr391.89M. The enterprise value is kr339.46M.

Corline Biomedical AB has 25,613,550 shares outstanding. The number of shares has decreased by -2.65% in one year.

Corline Biomedical AB’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -15.15%.

The current PE Ratio of Corline Biomedical AB is ―. Corline Biomedical AB’s PEG ratio is 0.62.

In the last 12 months, Corline Biomedical AB had revenue of 7.65M and earned -14.71M in profits. Earnings per share was -0.59.

In the last 12 months, operating cash flow was -17.69M and capital expenditures -47.00K, giving a free cash flow of -17.74M billion.

Corline Biomedical AB pays an annual dividend of ―, resulting in a dividend yield of ―

Corline Biomedical AB upcoming earnings date is May 8, 2026, TBA (Confirmed).

Corline Biomedical AB as a current ratio of 4.98, with Debt / Equity ratio of 0.00%

In the past 12 months, Corline Biomedical AB has paid 0.00 in taxes.

Corline Biomedical AB EV to EBITDA ratio is -27.26, with an EV/FCF ratio of -21.71.

Corline Biomedical AB has kr20.56M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr20.56M billion.

Gross margin is -3.40%, with operating margin of -185.70%, and net profit margin of -192.31%.

The average price target for Corline Biomedical AB is ―, which is 11.43% higher than the current price. The consensus rating is ―